Phase 2, Randomized, Double-Blind, Multiple-Dose Level, Placebo Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of NRX-1074 in Subjects With Major Depressive Disorder
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2018
Price : $35 *
At a glance
- Drugs Apimostinel (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Naurex
- 31 Aug 2018 Biomarkers information updated
- 22 Jun 2015 According to a Naurex Inc. media release, the results of this trial will be presented at the 55th Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP).
- 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.